Solebury Trout

Please note: The information displayed on this page might be outdated.
Solebury Trout: The Trout Group is the leading global investor relations and strategic advisory firm servicing the life sciences industry. Since 1996, the firm has been providing companies with expert counsel and access to the institutional investment community.

With almost two decades of experience in the biotechnology, pharmaceutical, medical technology and life science technology sectors, the Trout Group offers its clients the knowledge base needed to clarify investment themes and leverage key relationships for increased exposure to the proper audience. The firm’s global reach extends through a network of offices in New York, Boston, San Francisco, London, Sydney and Shanghai with contacts in all major financial centers, helping clients to connect with the right investors.
Service Provider
Based in...
US - Middle Atlantic
740 Broadway
9th Floor
New York, NY 10003
United States

Company Participants at 2020 Wall Street "On Tap"

Brian Korb
Solebury Trout, Managing Director
Brian Korb is a Managing Director based in New York. Since joining the firm in 2000, Brian has worked with hundreds of companies in the life sciences space, crafting and executing investor relations and communication plans. He is a trusted advisor who has helped raise over $500M for public and private companies in the U.S. and Europe through private placements, registered directs, convertible debt, royalty transactions, and secondary offerings. Brian leads efforts around Solebury Trout’s Annual Management Access event during the annual J.P. Morgan Healthcare Conference. He launched the firm’s popular U.S. and EU Wall Street Unplugged Conference series, EU Investor Tour, Pharma BD roundtable as well as the annual Solebury Trout Hamptons CEO Roundtable. Recent engagements include: * Advised a biotech company around their Phase 3 data announcement, conference call and subsequent key opinion leader event at a medical meeting * Managed and advised on four 4 private placements for Genfit, a Euronext listed company in France with a Phase 3 trial ongoing in NASH * Worked with Vivus and provided investor relations and strategic guidance around FDA Advisory Committee meetings, commercial launch and an activist investor crisis situation Brian graduated magna cum laude from Tufts University with a B.A. in psychology. He also holds Series 7, 24, 63 and 79 securities licenses. Brian has also completed more than 10 marathons and is an IRONMAN finisher. He is an active fundraiser for the Leukemia & Lymphoma Society, the Histiocytosis Association and the Achilles Foundation. He is a member of the National Eagle Scout Association. He resides in New York City with his wife and two young children.
Chad Rubin
Solebury Trout, Managing Director
Chad Recently joined joined Neximmune as SVP of Corporate Affairs in 2021. Chad has more than 22 years of experience in advising life science companies on topics including shareholder targeting, investor roadshows, capital markets transactions, messaging, and scenario analysis. His experience includes work in finance, consulting and market analysis, helping clients move from creation to follow-on and convertible offerings to M&A/IPO. Chad is involved in capital transactions with corporate clients and has counseled clients on domestic and cross-border transactions, and binary data events. Recent engagement and representation highlights include: * Advised a Phase 2 oncology company on release of clinical data, including KOL support/events, positioning and roadshows with the Wall Street community highlighting the data * Managed multiple private offerings for private life sciences and ag biotech companies from series A through series C * Managed multiple PIPEs for public clients * Assisted multiple companies through the pre-IPO process including strategy and support around messaging, materials, investor and analyst roadshows, syndicate selection and organizational support Prior to joining Solebury Trout in 2005, Chad was the head of the Biotechnology Capital Markets Intelligence Group at Thomson Financial, assisting life sciences companies in their understanding of Wall Street as it pertains to financing transactions, sales and trading dynamics, and perception around clinical and regulatory events. Chad holds a B.A. in Business Administration with a concentration in Finance from Franklin & Marshall College as well as a minor in Film and Media studies. Chad is a member of the Board of Trustees for the Histiocytosis Association and founder of “All Jacked Up,” an annual event that has raised more than $1M for research and awareness of histiocytic disorders. Chad holds Series 24, 7, 79 and 63 securities licenses. When not at work, Chad enjoys fishing, gardening, running, cycling, coaching lacrosse and football, playing guitar and hanging out with his family of five.
Thomas Hoffmann
Solebury Trout, Managing Director
Tommy’s knowledge of the European markets and his deep relationships with the European investment community has helped many of Solebury Trout’s clients expand their reach into Europe. Conversely, he also assists clients based outside the United States in navigating the U.S. biotech markets and developing their U.S. investor marketing strategies. Recent engagement highlights include: * Ongoing comprehensive investor relations services including providing counsel on IPOs and financings, developing road shows and implementing strategic plans. * Advising on both public and private company financings leading to investments of $400M+. * Delivering keynotes and leading several panels before domestic and international CEO and CFO audiences Tommy co-created Solebury Trout’s annual Hamptons CEO Roundtable and oversees Solebury Trout’s annual Management Access event at the J.P. Morgan Healthcare Conference in San Francisco. Tommy received an MBA from the University of Augsburg in Germany. He also holds Series 7 and 63 securities licenses.